AZTEC—azithromycin therapy for prevention of chronic lung disease of prematurity: a statistical analysis plan for clinical outcomes

BACKGROUND: The AZTEC trial is a multi-centre, randomised, placebo-controlled trial of azithromycin to improve survival without development of chronic lung disease of prematurity (CLD) in preterm infants. The statistical analysis plan for the clinical outcomes of the AZTEC trial is described. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Tin Man Mandy, Lowe, John, Pickles, Timothy, Hood, Kerenza, Kotecha, Sailesh, Gillespie, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Update
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396905/
https://www.ncbi.nlm.nih.gov/pubmed/35999617
http://dx.doi.org/10.1186/s13063-022-06604-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396905/
https://www.ncbi.nlm.nih.gov/pubmed/35999617
http://dx.doi.org/10.1186/s13063-022-06604-2

Ejemplares similares